腹膜后肉瘤诊疗规范、难点和发展方向——CSCO指南解读

摘要/Abstract

中图分类号:

刘文帅, 陆维祺, 周宇红. 腹膜后肉瘤诊疗规范、难点和发展方向——CSCO指南解读[J]. 外科理论与实践, 2022, 27(06): 483-489.

LIU Wenshuai, LU Weiqi, ZHOU Yuhong. Management of retroperitoneal sarcoma: rule, dilemma and perspectives-detailed interpretation of CSCO Guideline[J]. Journal of Surgery Concepts & Practice, 2022, 27(06): 483-489.

图/表1

参考文献59

[1]	The WHO Classification of Tumours Editorial Board. WHO Classification of Tumours Soft Tissue and Bone Tumours[M]. 5th ed. Lyon: IARC Press, 2020.
[2]	Swallow CJ, Strauss DC, Bonvalot S, et al. Management of primary retroperitoneal sarcoma (RPS) in the adult: an updated consensus approach from the Transatlantic Australasian RPS Working Group[J]. Ann Surg Oncol, 2021, 28(12):7873-7888. doi:10.1245/s10434-021-09654-zpmid:33852100
[3]	Gronchi A, Strauss DC, Miceli R, et al. Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative RPS Working Group[J]. Ann Surg, 2016, 263(5):1002-1009. doi:10.1097/SLA.0000000000001447pmid:26727100
[4]	Bonvalot S, Raut CP, Pollock RE, et al. Technical considerations in surgery for retroperitoneal sarcomas: position paper from E-Surge, a master class in sarcoma surgery, and EORTC-STBSG[J]. Ann Surg Oncol, 2012, 19(9):2981-2991. doi:10.1245/s10434-012-2342-2pmid:22476756
[5]	Bonvalot S, Rivoire M, Castaing M, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control[J]. J Clin Oncol, 2009, 27(1):31-37. doi:10.1200/JCO.2008.18.0802pmid:19047280
[6]	Lehnert T, Cardona S, Hinz U, et al. Primary and locally recurrent retroperitoneal soft-tissue sarcoma: local control and survival[J]. Eur J Surg Oncol, 2009, 35(9):986-993. doi:10.1016/j.ejso.2008.11.003pmid:19138832
[7]	Fairweather M, Wang J, Jo VY, et al. Incidence and adverse prognostic implications of histopathologic organ invasion in primary retroperitoneal sarcoma[J]. J Am Coll Surg, 2017, 224(5):876-883. doi:10.1016/j.jamcollsurg.2017.01.044 URL
[8]	Toulmonde M, Bonvalot S, Méeus P, et al. Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group[J]. Ann Oncol, 2014, 25(3):735-742. doi:S0923-7534(19)34269-3pmid:32018794
[9]	Mussi C, Colombo P, Bertuzzi A, et al. Retroperitoneal sarcoma: is it time to change the surgical policy?[J]. Ann Surg Oncol, 2011, 18(8):2136-2142. doi:10.1245/s10434-011-1742-zpmid:21537866
[10]	Fairweather M, Gonzalez RJ, Strauss D, et al. Current principles of surgery for retroperitoneal sarcomas[J]. J Surg Oncol, 2018, 117(1):33-41. doi:10.1002/jso.24919pmid:29315649
[11]	Gronchi A, Lo Vullo S, Fiore M, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients[J]. J Clin Oncol, 2009, 27(1):24-30. doi:10.1200/JCO.2008.17.8871pmid:19047283
[12]	Bonvalot S, Miceli R, Berselli M, et al. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control[J]. Ann Surg Oncol, 2010, 17(6):1507-1514. doi:10.1245/s10434-010-1057-5pmid:20393803
[13]	Tseng WW, Gronchi A. Surgery for recurrence in retroperitoneal leiomyosarcoma: is it all about selection?[J]. J Surg Oncol, 2017, 116(3):267-268. doi:10.1002/jso.24745pmid:28672078
[14]	Nathenson MJ, Barysauskas CM, Nathenson RA, et al. Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma[J]. World J Surg Oncol, 2018, 16(1):203. doi:10.1186/s12957-018-1505-4pmid:30309356
[15]	Rutkowski PL, Mullen JT. Management of the "Other" retroperitoneal sarcomas[J]. J Surg Oncol, 2018, 117(1):79-86. doi:10.1002/jso.24893pmid:29127695
[16]	Nessim C, Raut CP, Callegaro D, et al. Analysis of differentiation changes and outcomes at time of first recurrence of retroperitoneal liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)[J]. Ann Surg Oncol, 2021, 28(12):7854-7863. doi:10.1245/s10434-021-10024-ypmid:33907921
[17]	Trans-Atlantic RPS Working Group. Management of recurrent retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPS Working Group[J]. Ann Surg Oncol, 2016, 23(11):3531-3540. doi:10.1245/s10434-016-5336-7pmid:27480354
[18]	Rhu J, Cho CW, Lee KW, et al. Optimal maximum duration for delaying salvage operation when recurrence of retroperitoneal liposarcoma is suspected: a single-center study[J]. Int J Clin Oncol, 2019, 24(5):583-589. doi:10.1007/s10147-018-01383-wpmid:30604162
[19]	Siew CCH, Cardona K, van Houdt WJ. Management of recurrent retroperitoneal sarcomas[J]. Eur J Surg Oncol, 2022.[2022-11-18]. https://www.sciencedirect.com/science/article/abs/pii/S0748798322004929.
[20]	Dingley B, Fiore M, Gronchi A. Personalizing surgical margins in retroperitoneal sarcomas: an update[J]. Expert Rev Anticancer Ther, 2019, 19(7):613-631. doi:10.1080/14737140.2019.1625774 URL
[21]	Smith MJ, Ridgway PF, Catton CN, et al. Combined management of retroperitoneal sarcoma with dose intensification radiotherapy and resection: long-term results of a prospective trial[J]. Radiother Oncol, 2014, 110(1):165-171. doi:10.1016/j.radonc.2013.10.041pmid:24411227
[22]	Roeder F, Ulrich A, Habl G, et al. Clinical phase Ⅰ/Ⅱ trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma: interim analysis[J]. BMC Cancer, 2014, 14:617. doi:10.1186/1471-2407-14-617pmid:25163595
[23]	Cheng H, Miura JT, Lalehzari M, et al. Neoadjuvant radiotherapy for retroperitoneal sarcoma: a systematic review[J]. J Surg Oncol, 2016, 113(6):628-634. doi:10.1002/jso.24221pmid:26990903
[24]	Ma SJ, Oladeru OT, Farrugia MK, et al. Evaluation of preoperative chemotherapy or radiation and overall survival in patients with nonmetastatic, resectable retroperitoneal sarcoma[J]. JAMA Netw Open, 2020, 3(11):e2025529. doi:10.1001/jamanetworkopen.2020.25529 URL
[25]	Bonvalot S, Gronchi A, Le Péchoux C, et al. Preoperative radiotherapy plus surgeryversussurgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2020, 21(10):1366-1377. doi:S1470-2045(20)30446-0pmid:32941794
[26]	Donahue TR, Kattan MW, Nelson SD, et al. Evaluation of neoadjuvant therapy and histopathologic response in primary, high-grade retroperitoneal sarcomas using the sarcoma nomogram[J]. Cancer, 2010, 116(16):3883-3891. doi:10.1002/cncr.25271pmid:20564145
[27]	Tseng WW, Barretta F, Conti L, et al. Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: a multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group[J]. Cancer, 2021, 127(5):729-738. doi:10.1002/cncr.33323pmid:33206381
[28]	Istl AC, Gronchi A. Neoadjuvant therapy for primary resectable retroperitoneal sarcomas-looking forward[J]. Cancers (Basel), 2022, 14(7):1831. doi:10.3390/cancers14071831 URL
[29]	Judson I, Verweij J, Gelderblom H, et al. Doxorubicin aloneversusintensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial[J]. Lancet Oncol, 2014, 15(4):415-423. doi:10.1016/S1470-2045(14)70063-4pmid:24618336
[30]	Wong HH, Gounaris I, McCormack A, et al. Presentation and management of pulmonary artery sarcoma[J]. Clin Sarcoma Res, 2015, 5(1):3. doi:10.1186/s13569-014-0019-2 URL
[31]	Dangoor A, Seddon B, Gerrand C, et al. UK guidelines for the management of soft tissue sarcomas[J]. Clin Sarcoma Res, 2016, 6:20. doi:10.1186/s13569-016-0060-4 URL
[32]	Kawai A, Yonemori K, Takahashi S, et al. Systemic the-rapy for soft tissue sarcoma: proposals for the optimal use of pazopanib, trabectedin, and eribulin[J]. Adv Ther, 2017, 34(7):1556-1571. doi:10.1007/s12325-017-0561-4 URL
[33]	Lansu J, Bovée JVMG, Braam P, et al. Dose reduction of preoperative radiotherapy in myxoid liposarcoma: a nonrandomized controlled trial[J]. JAMA Oncol, 2021, 7(1):e205865. doi:10.1001/jamaoncol.2020.5865pmid:33180100
[34]	Chamberlain F, Benson C, Thway K, et al. Pharmacothe-rapy for liposarcoma: current and emerging synthetic treatments[J]. Future Oncol, 2021, 17(20):2659-2670. doi:10.2217/fon-2020-1092 URL
[35]	Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase Ⅲ randomized multicenter clinical trial[J]. J Clin Oncol, 2016, 34(8):786-793. doi:10.1200/JCO.2015.62.4734pmid:26371143
[36]	Schöffski P, Chawla S, Maki RG, et al. Eribulinversusdacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial[J]. Lancet, 2016, 387(10028):1629-1637. doi:10.1016/S0140-6736(15)01283-0pmid:26874885
[37]	van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial[J]. Lancet, 2012, 379(9829):1879-1886. doi:10.1016/S0140-6736(12)60651-5pmid:22595799
[38]	Mir O, Brodowicz T, Italiano A, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Oncol, 2016, 17(12):1732-1742. doi:S1470-2045(16)30507-1pmid:27751846
[39]	Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors[J]. J Hematol Oncol, 2016, 9(1):105. doi:10.1186/s13045-016-0332-8 URL
[40]	Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma[J]. Clin Cancer Res, 2018, 24(21):5233-5238. doi:10.1158/1078-0432.CCR-17-3766pmid:29895706
[41]	Wagner AJ, Ravi V, Riedel RF, et al. Nab-Sirolimus for patients with malignant perivascular epithelioid cell tumors[J]. J Clin Oncol, 2021, 39(33):3660-3670. doi:10.1200/JCO.21.01728 URL
[42]	Manji GA, van Tine BA, Lee SM, et al. A Phase Ⅰ study of the combination of pexidartinib and sirolimus to target tumor-associated macrophages in unresectable sarcoma and malignant peripheral nerve sheath tumors[J]. Clin Cancer Res, 2021, 27(20):5519-5527. doi:10.1158/1078-0432.CCR-21-1779 URL
[43]	Nacev BA, Jones KB, Intlekofer AM, et al. The epigenomics of sarcoma[J]. Nat Rev Cancer, 2020, 20(10):608-623. doi:10.1038/s41568-020-0288-4pmid:32782366
[44]	Schöffski P, Sufliarsky J, Gelderblom H, et al. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial[J]. Lancet Respir Med, 2018, 6(6):431-441. doi:10.1016/S2213-2600(18)30116-4pmid:29669701
[45]	Assi T, Rassy E, Nassereddine H, et al. TRK inhibition in soft tissue sarcomas: a comprehensive review[J]. Semin Oncol, 2020, 47(1):73-84. doi:S0093-7754(20)30011-7pmid:32201016
[46]	Nassif EF, Cope B, Traweek R, et al. Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center[J]. Int J Cancer, 2022, 150(12):2012-2024. doi:10.1002/ijc.33956pmid:35128664
[47]	Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial[J]. Lancet Oncol, 2017, 18(11):1493-1501. doi:S1470-2045(17)30624-1pmid:28988646
[48]	Boichard A, Wagner MJ, Kurzrock R. Angiosarcoma he-terogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing[J]. Genome Med, 2020, 12(1):61. doi:10.1186/s13073-020-00753-2pmid:32646514
[49]	Florou V, Rosenberg AE, Wieder E, et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution[J]. J Immunother Cancer, 2019, 7(1):213. doi:10.1186/s40425-019-0689-7pmid:31395100
[50]	Espejo-Freire AP, Elliott A, Rosenberg A, et al. Genomic landscape of angiosarcoma: a targeted and immunotherapy biomarker analysis[J]. Cancers (Basel), 2021, 13(19):4816. doi:10.3390/cancers13194816 URL
[51]	Zhu MMT, Shenasa E, Nielsen TO. Sarcomas: immune biomarker expression and checkpoint inhibitor trials[J]. Cancer Treat Rev, 2020, 91:102115. doi:10.1016/j.ctrv.2020.102115 URL
[52]	You Y, Guo X, Zhuang R, et al. Activity of PD-1 inhibitor combined with anti-angiogenic therapy in advanced sarcoma: a single-center retrospective analysis[J]. Front Mol Biosci, 2021, 8:747650. doi:10.3389/fmolb.2021.747650 URL
[53]	Betof Warner A, Palmer JS, Shoushtari AN, et al. Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade[J]. J Clin Oncol, 2020, 38(15):1655-1663. doi:10.1200/JCO.19.01464pmid:32053428
[54]	Grünewald TG, Alonso M, Avnet S, et al. Sarcoma treatment in the era of molecular medicine[J]. EMBO Mol Med, 2020, 12(11):e11131.
[55]	Dajsakdipon T, Siripoon T, Ngamphaiboon N, et al. Immunotherapy and biomarkers in sarcoma[J]. Curr Treat Options Oncol, 2022, 23(3):415-438. doi:10.1007/s11864-022-00944-6 URL
[56]	Keung EZ, Burgess M, Salazar R, et al. Correlative ana-lyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab[J]. Clin Cancer Res, 2020, 26(6):1258-1266. doi:10.1158/1078-0432.CCR-19-1824 URL
[57]	Petitprez F, Keung EZ, et al. B cells are associated with survival and immunotherapy response in sarcoma[J]. Nature, 2020, 577(7791):556-560. doi:10.1038/s41586-019-1906-8 URL
[58]	Carbone F, Pizzolorusso A, Di Lorenzo G, et al. Multidisciplinary management of retroperitoneal sarcoma: diagnosis, prognostic factors and treatment[J]. Cancers (Basel), 2021, 13(16):4016. doi:10.3390/cancers13164016 URL
[59]	Tseng WW, Pollock RE, Grignol VP. Disease biology is “king” in retroperitoneal liposarcoma[J]. Ann Surg Oncol, 2021, 28(Suppl 3):832-834. doi:10.1245/s10434-021-10472-6 URL

腹膜后肉瘤诊疗规范、难点和发展方向——CSCO指南解读

Management of retroperitoneal sarcoma: rule, dilemma and perspectives-detailed interpretation of CSCO Guideline

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表1

参考文献59

相关文章15

编辑推荐

Metrics

本文评价

[1]	严超, 陆晟, 燕敏, 朱正纲.《日本胃癌治疗指南2021（第6版）》解读及瑞金实践[J]. 外科理论与实践, 2023, 28(04): 326-354.
[2]	陶怡, 糜坚青.2023年美国国立综合癌症网络（NCCN）《多发性骨髓瘤指南》（第2版）更新解读[J]. 诊断学理论与实践, 2023, 22(02): 121-126.
[3]	陈骏, 罗成华.腹膜后肿瘤外科发展的历史、现状与前景展望[J]. 外科理论与实践, 2022, 27(06): 490-494.
[4]	李成鹏, 郝纯毅.积极推动我国腹膜后肉瘤临床研究开展的思考[J]. 外科理论与实践, 2022, 27(06): 495-499.
[5]	邱法波, 周斌, 曲腾飞.腹膜后肿瘤外科的规范及手术质量控制[J]. 外科理论与实践, 2022, 27(06): 526-529.
[6]	潘向欧, 张莉, 侯佳舟, 杜世锁, 曾昭冲, 王斌梁.切除困难或不可切除原发性腹膜后软组织肉瘤术前转化放射治疗的研究[J]. 外科理论与实践, 2022, 27(06): 530-533.
[7]	庄奥博, 童汉兴, 张勇, 陆维祺, 周宇红, 闾晨涛.老年原发性腹膜后软组织肉瘤病人手术治疗安全性分析的回顾性队列研究[J]. 外科理论与实践, 2022, 27(06): 534-539.
[8]	李贵森.2019年《中国慢性肾脏病矿物质和骨异常诊治指南》解读[J]. 诊断学理论与实践, 2020, 19(03): 229-231.
[9]	施仲伟.2016年欧美《超声心动图评价左心室舒张功能建议》新指南极大简化超声心动图评价左心室舒张功能[J]. 诊断学理论与实践, 2017, 16(01): 38-41.
[10]	纪元, 杜敏,.软组织肉瘤的分子分型及其临床意义[J]. 外科理论与实践, 2012, 17(04): 390-393.
[11]	侯英勇,.腹部软组织肉瘤的分期分级与治疗的相关意义[J]. 外科理论与实践, 2012, 17(04): 314-316.
[12]	赵如平, 姚伟强, 郭小毛,.腹膜后软组织肉瘤放疗现状及研究进展[J]. 外科理论与实践, 2012, 17(04): 386-389.
[13]	师英强,.重视腹腔及腹膜后肉瘤的诊治[J]. 外科理论与实践, 2012, 17(04): 297-300.
[14]	韩毓, 柴宇啸, 王奕静, 张怡, 曲兴龙,.隆突性皮肤纤维肉瘤的诊断和治疗(附22例报告)[J]. 外科理论与实践, 2010, 15(02): 173-174.
[15]	金晓龙,Shmookler BM,Jelinek J,丁晓毅,Malawer MM.四肢软组织高度恶性血肿样肉瘤15例临床病理研究[J]. 诊断学理论与实践, 2003, 2(03): 27-31.